Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy

Chimeric antigen receptor T-cell strategy targeting CD19 (CART19) has prominent anti-tumor effect for relapsed/refractory B-cell lymphomas. CART19-associated complications have been gradually recognized, however, late-onset complications have not been extensively studied. Herein, for the first time...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Res Treat
Autors principals: Hu, Yongxian, Wang, Jiasheng, Pu, Chengfei, Zhao, Kui, Cui, Qu, Wei, Guoqing, Wu, Wenjun, Xiao, Lei, Xiao, Yang, Wang, Jinping, Wu, Zhao, Huang, He
Format: Artigo
Idioma:Inglês
Publicat: Korean Cancer Association 2018
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6192928/
https://ncbi.nlm.nih.gov/pubmed/29397660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2017.473
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars